Clinical Trials Browser

Phase 1/2 × olutasidenib × 1 year × Clear all

NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Phase 1/2 Completed

336 enrolled 48 charts 1 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute